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Abstract
Background: evaluation of thyroid function in neonates born from mothers affected by autoimmune thyroiditis in
order to define if a precise follow-up is necessary for these children. The influence of maternal thyroid peroxidase
antibody (TPOAb) and L-thyroxine therapy during pregnancy on neonatal thyroid function was also investigated.
Methods: 129 neonates were tested for thyroid function by measurement of free thyroxine (FT4) and thyroid
stimulating hormone (TSH) in 3th day, 15th day and at one month of life. TPOAb were measured in all patients;
periodical control of thyroid function were performed until 6 months of life if Ab were positive. Data concerning
etiology of maternal hypothyroidism and maternal replacement therapy with L-thyroxine during pregnancy were
retrospectively collected.
Results: 28% neonates showed at least a mild increase of TSH value at the different determinations. In the majority
of them, a spontaneous completely normalisation of TSH value was observed within the first month life. L-
thyroxine replacement therapy was started in 3 neonates. TPOAb titer and maternal L-thyroxine replacement
therapy were not related to alteration of thyroid hormone function in our study population.
Conclusions: transient mild elevation of serum TSH above the normal reference value for age is frequently
observed in the first month of life in infants born from mothers affected by autoimmune thyroiditis. Persistent
hyperthyrotropinemia requiring replacement therapy is observed in 2.2% of these neonates. According to our
experience, follow-up is recommended in these newborns; the most accurate and not invasive way to carefully
monitor these infants after neonatal screening for CH seems to be serum-testing TSH between 2ndand 4th week of
life.
Background
During pregnancy there are many physiological changes
of maternal thyroid function. Hypothyroidism has been
reported in around 2.5% of otherwise normal pregnan-
cies [1,2] Hypothyroidism, if undiagnosed and untreated,
could cause not only obstetric complications, such as
hypertension, placental abruption, preterm delivery, low
birth weight, but also exposes fetus to low thyroid hor-
mone levels. The lack of maternal thyroid hormone dur-
ing early pregnancy might have some irreversible effects
on fetal development [3]. It is now clear that there is a
close relationship between maternal thyroid deficiencies
and the neuropsychological development of her child.
Several studies demonstrated that maternal hypothyroid-
ism was associated with impaired psychomotor and
intellectual development of the child [4-8]. In order to
reproduce the physiologic changes of thyroid function
during gestation, women with known hypothyroidism
and receiving L-thyroxine before pregnancy should
increase their dosage by 30% to 60% during pregnancy
[9,10].
The most common cause of hypothyroidism during
gestation is autoimmune thyroiditis, which is charac-
terised by the presence of specific thyroid autoantibo-
dies. The presence of thyroid peroxidase antibodies
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(TPOAb) is frequent associated to thyroiditis in women
of childbearing age; TPOAb have been found in 10% of
women during or shortly after pregnancy [11]. Dussault
et al reported that there is no correlation between the
presence of maternal antimicrosomal antibodies and
congenital hypothyroidism[12]; a further study con-
ducted in Quebec in 1999 demonstrated an increased
prevalence of transient congenital hypothyroidism asso-
ciated with maternal autoimmune thyroid disease, parti-
cularly antimicrosomal autoantibodies were found in
77% of mothers of infants with transient congenital
hypothyroidism[13]. Furthermore, the presence of
maternal TPOAb with normal maternal thyroid function
has been described in association with impaired neurop-
sychological development during early childhood [14].
Autoimmune thyroiditis characterised by the presence
of TSH receptor antibodies is a less frequent disorder
and its incidence in pregnancy is not well known.
Maternal-to-fetal transfer of TSH receptor-blocking
antibodies can lead to a rare condition of transient con-
genital hypothyroidism. The incidence of this disorder
in North America is 1 in 180.000 normal infants, or
approximately 2% of babies with congenital hypothyr-
oidism[15,16]; Prospective studies about thyroid func-
tion in neonates born from mothers affected by
autoimmune thyroiditis are not available in literature; in
particular is not yet known if maternal thyroiditis could
influence thyroid hormone levels of the neonate in the
first period of life. Even if cases of CH related to the
presence of maternal TSH-receptor antibodies are well
documented in literature as noted above, data about the
exact impact of maternal TPO-antibodies on neonatal
thyroid function are not available.
Considering the high incidence of TPOAb in pregnant
women, we aimed to establish if they could interfere with
neonatal thyroid function in order to standardize an
appropriate follow-up for these children. We also evalu-
ated the relationship between maternal replacement ther-
apy adjustment during pregnancy and newborn thyroid
function status during the first months of life.
Methods
Between April 2003 and May 2006, 129 neonates born
from mothers affected by autoimmune thyroiditis were
referred to Endocrinologic Neonatal Unit of Our Centre.
A longitudinal prospective study was conducted on this
population. Exclusion criteria for the study were: pre-
term delivery, perinatal asphyxia and congenital disease.
Data at birth including gestational age, delivery, Apgar
score, weight, lenght, head circumference, were
recorded.
Newborn screening for CH was performed and
recorded in all neonates included in the present study.
Regional screening program is conducted on filter paper
blood samples in 3-4 day of life by measurement of
TSH, with b-TSH cutoff of 10 mU/L.
TSH and FT4 on serum samples were measured in 3th
- 4th day of life and repeated at about 15 days of life
and at 30 days of life; TPOAb were determined concur-
rent with the sampling performed in 15th day. TSH and
FT4 measurement was repeated at 3 months and at 6
months of life if TPOAb were positive, or more closely
if thyroid hormone levels were not in the reference
range for age. TPOAb titer was reapeted at 6 months in
order to evaluate if the wash-out was completed. If anti-
bodies were negative and hormone levels resulted in the
reference range for age, follow up was stopped at one
month of life.
L-thyroxine replacement therapy was started if TSH
was persistently higher or FT4 lower than the reference
range for age according to Ranke’s reference range[17].
Neonates were investigated about the aetiology of CH
by performing thyroid scan, dosage of anti TSH receptor
antibodies and urinary iodine before treatment. Neurop-
sychological evaluation using Griffith’s scale was per-
formed in the neonates who underwent replacement
therapy between six months and one year of life.
Clinical and auxological examinations were performed
by the Pediatrician at one month of life in all neonates
and at 3 and at 6 months in children whose follow-up
continued for positive TPOAb or for thyroid hormone
levels alteration; the presence of symptoms and signs of
dysthyroidism was considered.
The diagnosis of maternal hypothyroidism was usually
performed by the referring physician before pregnancy
and by the ginecologist during gestation. Management
of these woman during pregnancy was conducted by
their endocrinologists or gynecologists/obstetricians.
Thyroid function was periodically measured during
gestation and L-thyroxine replacement therapy was
started or adjusted in order to maintain hormone levels
in the normal referring range. Informations about preg-
nancy were retrospectively collected from maternal ana-
mnestic history; at the first consultation, women were
asked about aetiology of hypothyroidism, about their
hormonal levels and L-thyroxine therapy management
during pregnancy. None of the Hashimoto’s affected
women referred to have low serum FT4 levels during
pregnancy.
Written informed consent was obtained from patients
for publication of this manuscript.
Collected data were expressed as median and range.
Results were analysed using Kruskall-Wallis test. Statis-
tics were performed using Sygma Stat.
Results
129 neonates (61 females, 68 males) born from mothers
affected by autoimmune thyroiditis were enrolled in the
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present study. All women referred to be biochemically
euthyroid throughout pregnancy; the dose of L-thyrox-
ine was increased during 88 pregnancies, 41 patients
mantained the dosage before pregnancy.
All neonates were born at term, at 39 median gesta-
tional week (range: 36 - 41+4 g.w.). Caesaren section
was performed in 41 cases.
Median birth weight was 3292.5 gr (range: 2100-4400
g), median lenght was 50 cm (range: 45-56 cm), median
head circumference was 34 cm (range: 31-44 cm); Apgar
score was ≥ 7 at one minute and at 5 minutes for all
children.
Neonatal screening for CH was negative in all patients
in our population.
FT4 value was in the normal reference range for age
at any determination in all neonates[17].
36/129 (28%) neonates showed at least a TSH value
higher than the reference range for age at different
blood testing during our follow-up. 27/36 (75%) of them
were born by spontaneous delivery; only 9 (25%) of
them were born by cesarean section.
In 3th - 4th day of life 30/129 neonates showed patho-
logic TSH value (median value: 11.86 mU/L, range 8,54
- 35.37 mU/L) considering the normal reference range
for age, with definitive spontaneous normalisation in 28
cases of them (93.3%) within 15 days of life (25 patients)
and one month of life (3 patients). 2 patients started
replacement therapy with L-thyroxine at about one
month of life for persistent mild elevation of TSH.
(Patients n. 1, 2 - Table 1)
In 15th day of life, 2/129 patients showed transient
mild increment of TSH value (9.86 mU/L in one case
and 11.8 mU/L in the other) which normalized at subse-
quent controls. One neonate whose TSH value was in
the normal reference range at the first determination in
3th day of life, showed TSH alteration (11.24 mU/L) in
15th day of life which was confirmed at a further control
performed a few days later (TSH 11.00 mU/L). L-
thyroxine replacement therapy was started at about 20
days of life in this case. (Patients n.3 in table 1)
3 other neonates showed transient isolated TSH eleva-
tion (6.5 - 10.0 - 10.1 mU/L) between one and three
months of age, which was not confirmed thereafter so
that therapy was not necessary.
TSH was normal at 6 months in non-treated children.
TPOAb were present in 73/129 neonates (59%) in 15th
day of life (normal range value 0-100 IU/ml). At 6
months of life autoantibodies were absent in all patients.
Considering 36 newborns with at least an alteration of
TSH, TPOAb were present in 17 (47%) of them.
As described above, replacement therapy with L-thyr-
oxine was started in 3/129 patients (2.2%). Before start-
ing therapy, neonates were investigated in order to
establish the diagnosis of their hyperthyrotropinemia.
All of them were born by spontaneous delivery. Normal
thyroid gland in situ was present in all neonates at thyr-
oid scan. TPOAb were present in two patients who
started replacement therapy and were absent in the
other; rTSH-Ab were absent in all neonates who started
therapy. None of them showed elevated values of urin-
ary iodine. After an appropriate discontinuation of ther-
apy between one and two years of life, all three patients
restore a normal thyroid function. Additionally their
neuropsychological development, evaluated between six
months and one year of life using Griffith’s scale,
resulted adequate (DQ 102-105).
We also evaluated the relation between maternal L-
thyroxine replacement therapy during pregnancy and
hormonal results of newborns. 88 neonates (68%) were
born from mothers whose therapy was increased during
gestation. Maternal therapy was adequately adjusted
during pregnancy in 30/36 neonates (83%) who showed
alteration of TSH.
All children showed normal auxological parameters
during our follow-up; neither signs of dysthyroidism or
medical problems were observed.
Discussion
The results of the present study indicate that mild thyr-
oid dysfunction characterized by TSH increase with nor-
mal FT4 level is frequently observed in the first month of
life in neonates born from mothers affected by autoim-
mune thyroiditis. The majority of them undergoes to
complete and spontaneous normalisation of TSH value.
Persistent hyperthyrotropinemia requiring replacement
therapy is demonstrated in 2.2% of these neonates. No
alteration of thyroid function was observed after the first
month of life in children who had positive TPOAb. The
limit of this paper is the lack of a control population.
TSH increase in 3th day of life is often transient; it
could be attributable to development of the hypothala-
mic-pituitary-thyroid axis at birth. In our study
Table 1 TSH value* at different determination during the
first month of life in neonates who started replacement
therapy
Patients TSH in 3th
day
TSH in 15th - 20th
day
TSH at about 1
month
n. 1 26.40 mU/L 10.95 mU/L 10.52 mU/L
Started therapy
n. 2 9.30 mU/L 8.18 mU/L 13.62 mU/L
Started therapy
n. 3 N 11.24 mU/L
(one week later:11)
Started therapy
* TSH normal reference value[17]:
< 1 month: 0,5-8,7 mU/ml
1 month - 1 year: 0,4-6,3 mU/ml
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population, complete normalisation of TSH value within
15-20 days of life was observed in 28/30 neonates
(93.3%) who showed a mild increase in 3th day of life.
Neonatal screening programs for CH, which is routinely
performed between 3-4 days of life in all newborns, pro-
vides a sufficient and available source for identification
of early TSH increment. Interestingly, one neonate who
resulted negative to the neonatal screening for CH and
whose TSH was normal at the first plasma TSH sam-
pling, showed TSH value above the normal reference
range in 15th day of life; TSH measurement was
repeated and confirmed, so that replacement therapy
was started at about one month of life. The only indica-
tion to blood testing this neonate for thyroid function
was maternal autoimmune thyroiditis, which allowed to
early identification of hyperthyrotropinemia. Our data
suggest that follow-up of neonates born from mothers
affected by autoimmune thyroiditis could be performed
by neonatal screening performed on filter blood sample
followed by measurement of TSH and FT4 on serum
between 2nd and 4th weeks of life in order to early iden-
tify any possible alteration of thyroid hormones. Some
screening programs routinely performed a second
screening in high-risk patient groups [18]. So in these
cases we suggest, as an alternative strategy, to repeat,
between 2nd and 4th weeks of life, the measurement of
TSH on filter paper.
In children that require therapy it would be helpful try
to stop therapy to value the transitoriness of the disease
and continue to monitor the child carefully and repeat
the thyroid function tests at the slightest suspicion of
recurrence of hypothyroid symptoms.
The presence of TPOAb in neonates with normal
TSH and in those with TSH alteration was similar in
our population. We didn’t demonstrate any relation
between TSH value and TPOAb presence/absence at
any blood testing and in neonates who started therapy
(TPOAb were present in 2 of them and negative in the
other). Our data are in agreement with other studies
[12], which showed the lack of influence of antibodies
on thyroid function in the newborn infant, and confirms
that TPOAb an TGAb apparently have no pathogenetic
effect on fetal and neonatal hypothyroidism [19].
Children were investigated about rTSH-Ab titer and
thyroid scan only if they showed persistent hyperthyro-
tropinemia in order to better define its etiology. rTSH-
Ab titer was measured in children who started therapy;
they were negative in all neonates who started replace-
ment therapy, indicating no influence of maternal
rTSH-Ab on neonatal thyroid function. Our data pro-
vide further evidence that rTSH-Ab dosage is not sys-
tematic recommended in infants born from mothers
affected by autoimmune thyroiditis, even if it remains
useful in all neonates who show persistent elevation of
TSH. The scan was performed to exclude severe gland’s
hypoplasia, any disomogeneity or ectopic glands, which
could represent a cause of thyroid function’s alteration.
Considering the potential benefit of L-thyroxine dose
adjustment in hypothyroid women during pregnancy in
determining the neuropsychological development of
the children [6,7] we evaluated maternal treatment
during pregnancy. Studies conducted on mothers of
congenitally hypothyroid infants showed that sup-
pressed and elevated TSH concentrations were more
frequent in the mothers of infant with congenital
hypothyroidism. We considered if adequacy of therapy
during pregnancy could influence neonatal thyroid
function. The results of the present study indicate that
adjustment of L-thyroxine treatment during pregnancy
was not related with thyroid function of the newborns.
Percentage of women who increased dosage of L-thyr-
oxine was similar in neonates with TSH alteration and
in neonates with normal TSH level during our follow-
up; furthermore neonates who started therapy were
born from mothers whose therapy has been increased
during pregnancy. We didn’t demonstrate a possible
influence of maternal on perinatal thyroid hormone
function; a longer follow-up is needed to evaluate the
impact of L-thyroxine treatment on neuropsychological
development of children.
Conclusion
In conclusion our data show the utility of monitoring
thyroid function in neonates born from mothers affected
by autoimmune thyroiditis. Our results confirm the pos-
sibility of mild alteration of TSH in the first months of
life, which could be difficulty diagnosed when signs or
symptoms are absent.
After neonatal screening for CH which is routinely
performed in all neonates by measurement of TSH or
TSH/FT4, the most prudent policy would be FT4 and
TSH serum testing between 2nd and 4th week of life in
all neonates born from mothers affected by autoimmune
thyroiditis; if hormone values resulted in the normal
referring range follow-up could be stopped. In addition
in children that require therapy it would be helpful try
to stop therapy to value the transitoriness of the disease
and continue to monitor the child carefully and repeat
the thyroid function tests at the slightest suspicion of
recurrence of hypothyroid symptoms. In order to obtain
helpful information regarding etiology and prognosis in
cases of persistent TSH abnormality we advice to mea-
sure TPOAb and/or rTSH-Ab and to perform thyroid
scan.
Further study are needed to evaluate the neuropsycho-
logical outcome of this children. Collaboration with
endocrinologist, gynecologist and neonatologist would
be necessary for a correct approach of women affected
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by hypothyroidism during pregnancy and for manage-
ment of the neonates during the first month of life.
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